<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946073</url>
  </required_header>
  <id_info>
    <org_study_id>HS-16-555</org_study_id>
    <nct_id>NCT02946073</nct_id>
  </id_info>
  <brief_title>Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain</brief_title>
  <acronym>CAM2038</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braeburn Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Camurus AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Braeburn Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment&#xD;
      withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced&#xD;
      subjects with moderate to severe CLBP that requires continuous, around-the-clock (ATC) opioid&#xD;
      treatment ≥ 40 mg morphine equivalent dose (MED). The study includes 5 phases: A Screening&#xD;
      Phase (up to 2 weeks), a Transition Phase (up to 2 weeks), an Open-Label Titration Phase (up&#xD;
      to 10 weeks), a Double-Blind Treatment Phase including a Final Study Visit (12 weeks), and a&#xD;
      Follow-up Phase (4 weeks). The overall duration of participation in the core phase of the&#xD;
      study (randomized Double-Blind Phase) is up to 30 weeks, from the Screening Phase through the&#xD;
      Follow-up Phase. Subjects who complete the Double-Blind Treatment Study Phase will be offered&#xD;
      an opportunity to continue treatment in an open label safety extension for up to 60 weeks.&#xD;
      Additional subjects may be recruited to open label safety extension to meet the goal of 100&#xD;
      subjects with 60 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase.</measure>
    <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
    <description>Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase.</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Weekly Average of (Daily) Worst Pain Intensity Scores at Week 12 of the Double-Blind Phase Based on 11-Point Numerical Rating Scale With 10 Being the Worst Pain.</measure>
    <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
    <description>Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a 30% and 50% Reduction in WAAPI From Baseline to Week 12 of the Double-Blind Phase.</measure>
    <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
    <description>Number of Responders With a 30% and 50% Reduction in WAAPI from the Open-Label Titration Period Baseline to Week 12 of the Double-Blind Treatment Period (mITT Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Rescue Medication Usage- Double-Blind Phase.</measure>
    <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
    <description>Rescue medication usage (number of days used) during the Double-Blind Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Open Label Titration Baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level Self-report Questionnaire Score.</measure>
    <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
    <description>Change from Open Label Titration baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level self-report questionnaire score. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment Score</measure>
    <time_frame>23 weeks- from baseline to 12 weeks after randomization</time_frame>
    <description>Change from baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment score. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed)，Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism)，and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Discontinued Due to Loss of Efficacy</measure>
    <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
    <description>Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 of the Double-Blind Phase in Patient Global Impression of Improvement (PGI-I) Scale</measure>
    <time_frame>12 weeks- from baseline (randomization) to 12 weeks after randomization</time_frame>
    <description>Change from baseline to Week 12 of the Double-Blind Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I)Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study at the beginning of the intervention . Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) of the Open Label Phase.</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 52 of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy.</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy Open Label Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Rescue Medication Usage-Open Label Phase</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Rescue medication usage (number of days used) during the Open Label Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline in EuroQoL Group EQ-5D-5L Scores Over Time-Open Label Phase</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Change from Open Label Titration baseline in EuroQol Group 5-dimension 5-level self-report questionnaire score in the Open Label Phase. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale-Open Label</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Summary of Change from Baseline in Clinical Global Impression of Improvement (CGI-I) scale. The Clinician Global Impression of Improvement (CGI-I) Scale is a 7-point scale that required the clinician to assess how much the subject's Pain had improved or worsened relative to the start of the study. Assessments were rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline in Patient Global Impression of Improvement (PGI-I) Scale</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Change from baseline in the Open Label Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study. Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Open Label Phase</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Change from baseline in the Open Label Phase in Work Productivity and Activity Impairment score with a range of 0-100 for 4 types of scores with higher scores indicating greater impairment. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed)，Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism)，and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Discontinued Due to Loss of Efficacy</measure>
    <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
    <description>Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Chronic Lower Back Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CAM2038 placebo injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAM2038</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine</intervention_name>
    <arm_group_label>CAM2038</arm_group_label>
    <other_name>CAM2038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent provided prior to the conduct of any study-related&#xD;
             procedures.&#xD;
&#xD;
          2. Male or non-pregnant, non-lactating female subject, greater than or equal to 18 years&#xD;
             old.&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 38 kg/m2, inclusive.&#xD;
&#xD;
          4. Treated with daily opioids for moderate to severe CLBP for a minimum of 3 months prior&#xD;
             to Screening.&#xD;
&#xD;
          5. On a stable dose of ≥40 mg/day of oral morphine or MED during the 14 days prior to&#xD;
             Screening.&#xD;
&#xD;
          6. Systolic blood pressure ≥100 mmHg and diastolic blood pressure ≥60 mmHg.&#xD;
&#xD;
          7. Female subject of childbearing potential who is willing to use a reliable method of&#xD;
             contraception during the entire study (Screening Visit to final Follow-up). To be&#xD;
             considered not of childbearing potential, female subjects must be surgically sterile&#xD;
             (hysterectomy or bilateral oophorectomy, or bilateral tubal ligation with surgery at&#xD;
             least 6 weeks before Screening).&#xD;
&#xD;
          8. Male subject who is willing to use reliable contraception&#xD;
&#xD;
          9. Willing and able to comply with all study procedures and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive for hepatitis B surface antigen, hepatitis C viral RNA, or antibodies to&#xD;
             human immunodeficiency virus (HIV).&#xD;
&#xD;
          2. Clinically significant symptoms, medical conditions, or other circumstances which, in&#xD;
             the opinion of the investigator, would preclude compliance with the protocol, adequate&#xD;
             cooperation in the study, or obtaining informed consent, or may prevent the subject&#xD;
             from safely participating in the study, including the following:&#xD;
&#xD;
               1. Severe respiratory insufficiency, respiratory depression, airway obstruction,&#xD;
                  gastrointestinal motility disorders, biliary tract disease, severe hepatic&#xD;
                  insufficiency, or planned surgery.&#xD;
&#xD;
               2. Bipolar disorder&#xD;
&#xD;
          3. Current diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth&#xD;
             Edition-defined moderate to severe substance use disorder (including alcohol), other&#xD;
             than caffeine or nicotine.&#xD;
&#xD;
          4. Female subject planning to become pregnant during the study.&#xD;
&#xD;
          5. Surgical procedure(s) for CLBP within 6 months prior to Screening.&#xD;
&#xD;
          6. Concomitant disease(s) that could prolong the QTcF interval, such as autonomic&#xD;
             neuropathy (caused by diabetes or Parkinson's disease), HIV, cirrhosis, Long QT&#xD;
             Syndrome, or family history of Long QT Syndrome.&#xD;
&#xD;
          7. QTcF &gt;450 ms for males and &gt;470 ms for females, or clinically significant&#xD;
             electrocardiogram (ECG) abnormality at Screening, at the investigator's discretion.&#xD;
&#xD;
          8. Currently taking medications that have the potential to prolong the QTcF interval or&#xD;
             may require such medications during the course of the study (Appendix 1) and has&#xD;
             clinically significant abnormalities on screening ECG readings, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          9. A nerve or plexus block, including epidural steroid injections or facet blocks, within&#xD;
             1 month prior to Screening or botulinum toxin injection in the lower back region&#xD;
             within 3 months of Screening.&#xD;
&#xD;
         10. History of chemotherapy or confirmed malignancy (except basal cell carcinoma) within&#xD;
             the past 2 years.&#xD;
&#xD;
         11. Any other acute or chronic pain condition that could interfere with the subject's&#xD;
             ability to report their CLBP accurately and consistently and/or interfere with the&#xD;
             study staff's ability to assess the subjects CLBP.&#xD;
&#xD;
         12. An active or pending workman's compensation, insurance claim, or litigation related to&#xD;
             back pain (i.e., primary claim is back pain).&#xD;
&#xD;
         13. Clinically significant history, in the opinion of the investigator, of suicidal&#xD;
             ideation or current evidence that the subject is actively suicidal.&#xD;
&#xD;
         14. Clinically significant history of major depressive disorder that is poorly controlled&#xD;
             with medication, per investigator judgment.&#xD;
&#xD;
         15. Hypersensitivity or allergy to BPN, other opioids, or excipients of CAM2038.&#xD;
&#xD;
         16. Hypersensitivity or allergy to acetaminophen.&#xD;
&#xD;
         17. Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), such as some&#xD;
             azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., clarithromycin),&#xD;
             or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) within the 30 days&#xD;
             prior to Screening,&#xD;
&#xD;
         18. Use or planned use of natural supplements that can affect CYP3A4, such as St. John's&#xD;
             Wort, throughout the study.&#xD;
&#xD;
         19. Has a major bleeding disorder, such as hemophilia, or treated with high levels of&#xD;
             anticoagulants per the investigator's discretion.&#xD;
&#xD;
         20. Current or confirmed past diagnosis of Sphincter of Oddi dysfunction.&#xD;
&#xD;
         21. Has a significant hepatic disease, as indicated by Screening clinical laboratory&#xD;
             assessment results (aspartate aminotransferase, alanine aminotransferase, or lactate&#xD;
             dehydrogenase values ≥3 × the upper limit of normal [ULN]) or has a creatinine value&#xD;
             ≥1.5 × ULN).&#xD;
&#xD;
         22. Is an employee of the investigator or the trial site, with direct involvement in the&#xD;
             proposed trial or other studies under the direction of the investigator or trial site&#xD;
             or is a family member of the investigator or of an employee of the investigator.&#xD;
&#xD;
         23. Has any pending legal action that could prohibit participation or compliance in the&#xD;
             study.&#xD;
&#xD;
        Criteria for Entry into the Titration Phase:&#xD;
&#xD;
          1. After at least a 12-hour washout from the last IR morphine dose, subject must have a&#xD;
             COWS ≥5 and an API pain score over the past 24 hours ≥5 in order to receive a test&#xD;
             dose of Buprenex.&#xD;
&#xD;
          2. Passed all baseline criteria, including a normal QTcF, had no change in QTcF &gt;30 ms at&#xD;
             1 hour after the test dose with Buprenex, and had a COWS score &lt;5 after the test dose&#xD;
             with Buprenex.&#xD;
&#xD;
        Note:&#xD;
&#xD;
          -  Subjects on BPN at Screening are required to participate in the down titration and&#xD;
             will undergo a washout period prior to the test dose and first on-study treatment.&#xD;
             Subjects entering the study on BPN will not transition to IR Morphine, but will&#xD;
             refrain from taking their BPN for 12 -24 hours prior to the test dose to achieve the&#xD;
             desired washout period.&#xD;
&#xD;
          -  Subjects on BPN at Screening are still required to follow the same Day 1 procedures&#xD;
             (e.g., confirmation of pain scores, COWS assessment and Buprenex test dose) as non-BPN&#xD;
             subjects.&#xD;
&#xD;
        Criteria for Randomization into the Double-Blind Phase:&#xD;
&#xD;
          1. Been on a stable dose of CAM2038 q1w for at least 2 consecutive weeks.&#xD;
&#xD;
          2. CAM2038 titrated to a dose that provides analgesia (i.e., 7-day API score of ≤4 and at&#xD;
             least 2 points below the value at the start of Titration Phase) and is well tolerated&#xD;
             for 7 days before randomization.&#xD;
&#xD;
          3. Requires no more than an average of one hydrocodone/acetaminophen 5 mg/325 mg/day&#xD;
             during the last 7 days prior to randomization.&#xD;
&#xD;
          4. Demonstrated study medication (CAM2038) compliance ≥80% during the previous 14 days.&#xD;
&#xD;
          5. Demonstrated daily compliance with pain intensity scoring for ≥11 of the previous 14&#xD;
             days, including the last 3 days prior to randomization.&#xD;
&#xD;
        Inclusion Criteria for Open Label Extension For Subjects Continuing from The Randomized&#xD;
        Double-Blind Phase.&#xD;
&#xD;
        Subjects must have:&#xD;
&#xD;
          1. Completed Double Blind Phase of the study&#xD;
&#xD;
          2. Signed Informed Consent for Safety Extension&#xD;
&#xD;
        Subjects completing the double-blind phase will be enrolled directly into the open label&#xD;
        extension at their respective dose level of CAM2038. They will not be required to&#xD;
        participate in a Buprenex treatment test dosing or participate in a titration phase.&#xD;
&#xD;
        For De Novo Subjects (New Subjects Recruited Directly into The Open Label Extension)&#xD;
&#xD;
        Subjects who are not participating in the Double-Blind Phase of the Study must meet all of&#xD;
        the following inclusion criteria in order to be eligible for participation in the study:&#xD;
&#xD;
          1. Written informed consent provided prior to the conduct of any study-related&#xD;
             procedures.&#xD;
&#xD;
          2. Male or non-pregnant and non-lactating female subject, greater than or equal to 18&#xD;
             years old.&#xD;
&#xD;
          3. BMI between 18 and 38 kg/m2, inclusive.&#xD;
&#xD;
          4. Treated with daily opioids for moderate to severe chronic pain disorder such as CLBP&#xD;
             or osteoarthritis for a minimum of 3 months prior to Screening.&#xD;
&#xD;
          5. On a stable dose of &gt;40 mg/day of oral morphine or MED during the 14 days prior to&#xD;
             Screening.&#xD;
&#xD;
          6. Systolic blood pressure ≥100 mmHg and diastolic blood pressure ≥60 mmHg.&#xD;
&#xD;
          7. Female subject of childbearing potential who is willing to use a reliable method of&#xD;
             contraception during the entire study (Screening Visit to final Follow-up). To be&#xD;
             considered not of childbearing potential, female subjects must be surgically sterile&#xD;
             (hysterectomy or bilateral oophorectomy, or bilateral tubal ligation with surgery at&#xD;
             least 6 weeks before Screening).&#xD;
&#xD;
          8. Male subject who is willing to use reliable contraception&#xD;
&#xD;
          9. Willing and able to comply with all study procedures and requirements.&#xD;
&#xD;
        Exclusion Criteria for Subjects Continuing from The Randomized Double-Blind Phase&#xD;
&#xD;
        1. Clinically significant symptoms, medical conditions, or other circumstances which, in&#xD;
        the opinion of the investigator, would preclude compliance with the protocol, adequate&#xD;
        cooperation in the study, or obtaining informed consent, or may prevent the subject from&#xD;
        safely participating in the study.&#xD;
&#xD;
        Exclusion Criteria for De Novo Subjects only:&#xD;
&#xD;
        Same exclusion criteria as for subjects participating in the Randomized Double-Blind&#xD;
        Treatment Phase.&#xD;
&#xD;
        Criteria for Entry into the Titration Phase (for De novo subjects):&#xD;
&#xD;
          1. After at least a 12-hour washout from the last IR morphine dose, subject should have a&#xD;
             COWS ≥5 and an API pain score over the past 24 hours ≥5 in order to receive a test&#xD;
             dose of Buprenex.&#xD;
&#xD;
          2. Passed all baseline criteria, including a normal QTcF, had no change in QTcF &gt;30 ms at&#xD;
             1 hour after the test dose with Buprenex, and had a COWS score &lt;5 after the test dose&#xD;
             with Buprenex.&#xD;
&#xD;
        Note:&#xD;
&#xD;
          -  Subjects on BPN at Screening are required to participate in the down titration and&#xD;
             will undergo a washout period prior to the test dose and first on-study treatment.&#xD;
             Subjects entering the study on BPN will not transition to IR Morphine, but will&#xD;
             refrain from taking their BPN for 12 -24 hours prior to the test dose to achieve the&#xD;
             desired washout period.&#xD;
&#xD;
          -  However, subjects on BPN at Screening are still required to follow the same Day 1&#xD;
             procedures (e.g., confirmation of pain scores, COWS assessment and Buprenex test dose)&#xD;
             as non-BPN subjects.&#xD;
&#xD;
        Criteria for Enrolment into the Open Label Treatment Phase (for de Novo subjects):&#xD;
&#xD;
          1. Been on a stable dose of CAM2038 q1w for at least 2 consecutive weeks.&#xD;
&#xD;
          2. CAM2038 titrated to a dose that provides analgesia (i.e., 7-day API score of ≤4 and at&#xD;
             least 2 points below the value at the start of Titration Phase) and is well tolerated&#xD;
             for 7 days before randomization.&#xD;
&#xD;
          3. Requires no more than an average of one hydrocodone/acetaminophen 5 mg/325 mg/day&#xD;
             during the last 7 days prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parkway Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boyett Health Services Inc</name>
      <address>
        <city>Hamilton</city>
        <state>Alabama</state>
        <zip>35570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Centers for Pain Management and Research</name>
      <address>
        <city>Vestavia Hills</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Clinical</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noesis Pharma</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Studies, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Centers</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Research, LLC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95842</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Practice</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universal Pain Management Group</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Pain Relief Center-Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Partners</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Vijapura and Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Institute of Medical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Howell Health Center</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Medical Research Center, Inc.</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research, LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMPM Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Pain Relief Centers-Hillsborough</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Birch Research Alliance LLC</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Georgia</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Studies America</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-Surgical Orthopedics, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Injury Care Research, LLC</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.-Gurnee</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Institute Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otrimed</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Cities Clinical Research Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Paincare</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amicis Trials</name>
      <address>
        <city>Festus</city>
        <state>Missouri</state>
        <zip>63028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials, Inc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEx Healthcare Research, Inc-NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapha Institute for Clinical Research</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC-Hickory</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, LLC-Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Outpatient Center (DOC) Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Partners-Center for Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Internationl</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Research, PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frost Medical Group, LLC</name>
      <address>
        <city>Conshohocken</city>
        <state>Pennsylvania</state>
        <zip>19428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Research Associates</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South, LLC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renaissance Clinical Research and Hypertension Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Concepts GP, LLC-Houstion</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pain Relief Center</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The SMART Clinic/Physicians Research Options LLC</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPIC Medical Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Columbia Research</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <results_first_submitted>October 7, 2020</results_first_submitted>
  <results_first_submitted_qc>September 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2021</results_first_posted>
  <disposition_first_submitted>January 29, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 7, 2020</disposition_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02946073/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02946073/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>965 of those subjects entered the Double Blind phase of the study. 108 subjects signed consent as De Novo subjects, but 20 of those subjects were part of the Double Blind phase. The total number of subjects that signed consent was 1053 (965 + 88).Two sites had quality issues with the data, so those subjects were eliminated from the analysis. This made the total number of subjects who were analyzed 222 in the double blind randomized phase and 132 subjects for the open label phase.</recruitment_details>
      <pre_assignment_details>Subjects are screened prior to entry into a titration phase where they are titrated to an appropriate dose. Once they are titrated, they were randomized and entered the double blind period or open label period for de novo subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CAM2038 q1w or q4w BPN Treatment- Double Blind Phase</title>
          <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg. buprenorphine</description>
        </group>
        <group group_id="P2">
          <title>Placebo Subcutaneous Injections-Double Blind Phase</title>
          <description>CAM2038 placebo: 0.16, 0.18, 0.24, 0.27, 0.36, and 0.64 mL SC injection administered once weekly or once monthly</description>
        </group>
        <group group_id="P3">
          <title>De Novo Subjects-Open Label Phase</title>
          <description>De Novo subjects proceeded directly from the Open-Label Titration Period to the Open-Label Safety Extension Phase without participating in the Double-Blind Treatment Period. CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
        </group>
        <group group_id="P4">
          <title>Rollover Subjects-Open Label</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Titration Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="811"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="589"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Double Blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CAM2038 q1w or q4w BPN Treatment- Double Blind Phase</title>
          <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg. buprenorphine</description>
        </group>
        <group group_id="B2">
          <title>Placebo Subcutaneous Injections-Double Blind Phase</title>
          <description>CAM2038 placebo: 0.16, 0.18, 0.24, 0.27, 0.36, and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
        </group>
        <group group_id="B3">
          <title>De Novo Subjects-Open Label</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
        </group>
        <group group_id="B4">
          <title>Rollover Subjects-Open Label</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Double Blind Phase Only</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="112"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="12.19"/>
                    <measurement group_id="B2" value="54.7" spread="11.36"/>
                    <measurement group_id="B5" value="54.2" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Open Label Phase Only</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="75"/>
                    <count group_id="B4" value="57"/>
                    <count group_id="B5" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="54.3" spread="10.27"/>
                    <measurement group_id="B4" value="56.4" spread="11.49"/>
                    <measurement group_id="B5" value="55.2" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Double Blind Phase only.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="112"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B5" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Open Label Phase Only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="75"/>
                    <count group_id="B4" value="57"/>
                    <count group_id="B5" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Double Blind Phase Only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="112"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Open Phase Only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="75"/>
                    <count group_id="B4" value="57"/>
                    <count group_id="B5" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Double Blind Phase Only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="112"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B5" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Open Label Phase Only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="75"/>
                    <count group_id="B4" value="57"/>
                    <count group_id="B5" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters.</description>
          <population>Double Blind Phase Only</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="112"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="4.78"/>
                    <measurement group_id="B2" value="29.3" spread="5.27"/>
                    <measurement group_id="B5" value="29.2" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters.</description>
          <population>Open Label Phase Only</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="75"/>
                    <count group_id="B4" value="57"/>
                    <count group_id="B5" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="29.5" spread="5.55"/>
                    <measurement group_id="B4" value="29.1" spread="5.29"/>
                    <measurement group_id="B5" value="29.3" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Score at Start of Open-Label Titration Period</title>
          <description>11- Point Numerical Rating Scale (NRS-11)- an 11-point scale with anchors at 0 (no pain) and 10 (worst pain imaginable) to measure pain.</description>
          <population>Double Blind Phase Only</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="112"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="1.42"/>
                    <measurement group_id="B2" value="7.0" spread="1.39"/>
                    <measurement group_id="B5" value="7.0" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Score at Start of Open-Label Titration Period</title>
          <description>11- Point Numerical Rating Scale (NRS-11)- an 11-point scale with anchors at 0 (no pain) and 10 (worst pain imaginable) to measure pain.</description>
          <population>Open Label Phase Only</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="75"/>
                    <count group_id="B4" value="57"/>
                    <count group_id="B5" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="6.7" spread="1.46"/>
                    <measurement group_id="B4" value="6.6" spread="1.73"/>
                    <measurement group_id="B5" value="6.7" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase.</title>
        <description>Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain.</description>
        <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038 (Buprenorphine FluidCrystal®) q1w and q4w</title>
            <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Subcutaneous Injections</title>
            <description>CAM2038 placebo: 0.16, 0.18, 0.24, 0.27, 0.36, and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase.</title>
          <description>Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.26"/>
                    <measurement group_id="O2" value="2.4" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.62"/>
                    <measurement group_id="O2" value="-1.9" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase.</title>
        <description>Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase.</title>
          <description>Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.839" spread="1.0753"/>
                    <measurement group_id="O2" value="2.256" spread="1.1642"/>
                    <measurement group_id="O3" value="1.944" spread="1.1288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.434" spread="0.94"/>
                    <measurement group_id="O2" value="-0.531" spread="0.93"/>
                    <measurement group_id="O3" value="-1.586" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.555" spread="1.28"/>
                    <measurement group_id="O2" value="-0.729" spread="0.99"/>
                    <measurement group_id="O3" value="-2.165" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.752" spread="1.35"/>
                    <measurement group_id="O2" value="-0.767" spread="1.20"/>
                    <measurement group_id="O3" value="-2.079" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.543" spread="1.19"/>
                    <measurement group_id="O2" value="-0.312" spread="0.68"/>
                    <measurement group_id="O3" value="-1.229" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.690" spread="1.47"/>
                    <measurement group_id="O2" value="-0.566" spread="1.05"/>
                    <measurement group_id="O3" value="-1.013" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.718" spread="1.46"/>
                    <measurement group_id="O2" value="-0.872" spread="1.51"/>
                    <measurement group_id="O3" value="-1.220" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.905" spread="1.56"/>
                    <measurement group_id="O2" value="-0.338" spread="1.06"/>
                    <measurement group_id="O3" value="-1.212" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.941" spread="1.64"/>
                    <measurement group_id="O2" value="-0.275" spread="1.41"/>
                    <measurement group_id="O3" value="-1.111" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.920" spread="1.48"/>
                    <measurement group_id="O2" value="-0.623" spread="1.36"/>
                    <measurement group_id="O3" value="-1.119" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.913" spread="1.37"/>
                    <measurement group_id="O2" value="-0.519" spread="1.51"/>
                    <measurement group_id="O3" value="-1.113" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.767" spread="1.32"/>
                    <measurement group_id="O2" value="-0.560" spread="1.37"/>
                    <measurement group_id="O3" value="-1.282" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.996" spread="1.39"/>
                    <measurement group_id="O2" value="-0.619" spread="1.58"/>
                    <measurement group_id="O3" value="-1.215" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Weekly Average of (Daily) Worst Pain Intensity Scores at Week 12 of the Double-Blind Phase Based on 11-Point Numerical Rating Scale With 10 Being the Worst Pain.</title>
        <description>Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain.</description>
        <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo: 0.16, 0.18, 0.24, 0.27, 0.36, and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Weekly Average of (Daily) Worst Pain Intensity Scores at Week 12 of the Double-Blind Phase Based on 11-Point Numerical Rating Scale With 10 Being the Worst Pain.</title>
          <description>Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.59"/>
                    <measurement group_id="O2" value="3.7" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.81"/>
                    <measurement group_id="O2" value="-2.2" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a 30% and 50% Reduction in WAAPI From Baseline to Week 12 of the Double-Blind Phase.</title>
        <description>Number of Responders With a 30% and 50% Reduction in WAAPI from the Open-Label Titration Period Baseline to Week 12 of the Double-Blind Treatment Period (mITT Population)</description>
        <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo injections&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a 30% and 50% Reduction in WAAPI From Baseline to Week 12 of the Double-Blind Phase.</title>
          <description>Number of Responders With a 30% and 50% Reduction in WAAPI from the Open-Label Titration Period Baseline to Week 12 of the Double-Blind Treatment Period (mITT Population)</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 30% improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50% improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Rescue Medication Usage- Double-Blind Phase.</title>
        <description>Rescue medication usage (number of days used) during the Double-Blind Phase.</description>
        <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo injections&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Rescue Medication Usage- Double-Blind Phase.</title>
          <description>Rescue medication usage (number of days used) during the Double-Blind Phase.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.84"/>
                    <measurement group_id="O2" value="3.5" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.58"/>
                    <measurement group_id="O2" value="-2.1" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Open Label Titration Baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level Self-report Questionnaire Score.</title>
        <description>Change from Open Label Titration baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level self-report questionnaire score. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health.</description>
        <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo injections&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Open Label Titration Baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level Self-report Questionnaire Score.</title>
          <description>Change from Open Label Titration baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level self-report questionnaire score. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Titration Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" spread="20.55"/>
                    <measurement group_id="O2" value="61.3" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="18.47"/>
                    <measurement group_id="O2" value="-7.2" spread="23.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment Score</title>
        <description>Change from baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment score. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed)，Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism)，and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment.</description>
        <time_frame>23 weeks- from baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo injections&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment Score</title>
          <description>Change from baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment score. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed)，Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism)，and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline-Activity Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" spread="23.68"/>
                    <measurement group_id="O2" value="61.2" spread="22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12 after randomization-Activity impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="24.88"/>
                    <measurement group_id="O2" value="11.7" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-Absenteesim</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="10.19"/>
                    <measurement group_id="O2" value="9.9" spread="22.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12 after randomization-Absenteesim</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="10.75"/>
                    <measurement group_id="O2" value="-4.6" spread="22.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="22.33"/>
                    <measurement group_id="O2" value="47.8" spread="25.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12 after randomization-Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="27.47"/>
                    <measurement group_id="O2" value="9.0" spread="27.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-Work Productivity Loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="23.09"/>
                    <measurement group_id="O2" value="52.3" spread="26.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12 after randomization- Work Productivity Loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="23.05"/>
                    <measurement group_id="O2" value="7.8" spread="26.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Discontinued Due to Loss of Efficacy</title>
        <description>Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.</description>
        <time_frame>12 weeks- from randomization baseline to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo injections&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discontinued Due to Loss of Efficacy</title>
          <description>Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 of the Double-Blind Phase in Patient Global Impression of Improvement (PGI-I) Scale</title>
        <description>Change from baseline to Week 12 of the Double-Blind Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I)Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study at the beginning of the intervention . Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better</description>
        <time_frame>12 weeks- from baseline (randomization) to 12 weeks after randomization</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>CAM2038 placebo injections&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 of the Double-Blind Phase in Patient Global Impression of Improvement (PGI-I) Scale</title>
          <description>Change from baseline to Week 12 of the Double-Blind Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I)Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study at the beginning of the intervention . Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="0.96"/>
                    <measurement group_id="O2" value="6.2" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.48"/>
                    <measurement group_id="O2" value="1.5" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) of the Open Label Phase.</title>
        <description>Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 52 of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) of the Open Label Phase.</title>
          <description>Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 52 of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.139" spread="1.55"/>
                    <measurement group_id="O2" value="3.717" spread="3.86"/>
                    <measurement group_id="O3" value="3.246" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.517" spread="1.34"/>
                    <measurement group_id="O2" value="-0.859" spread="1.57"/>
                    <measurement group_id="O3" value="-1.734" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.625" spread="1.48"/>
                    <measurement group_id="O2" value="-1.066" spread="1.68"/>
                    <measurement group_id="O3" value="-2.404" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.846" spread="1.53"/>
                    <measurement group_id="O2" value="-1.157" spread="1.95"/>
                    <measurement group_id="O3" value="-2.455" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.689" spread="1.51"/>
                    <measurement group_id="O2" value="-0.487" spread="1.14"/>
                    <measurement group_id="O3" value="-1.587" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.725" spread="1.59"/>
                    <measurement group_id="O2" value="-0.592" spread="1.157"/>
                    <measurement group_id="O3" value="-1.391" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.735" spread="1.67"/>
                    <measurement group_id="O2" value="-0.902" spread="2.13"/>
                    <measurement group_id="O3" value="-1.461" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.013" spread="1.55"/>
                    <measurement group_id="O2" value="-0.518" spread="1.74"/>
                    <measurement group_id="O3" value="-1.531" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.996" spread="1.90"/>
                    <measurement group_id="O2" value="-0.322" spread="1.76"/>
                    <measurement group_id="O3" value="-1.462" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.044" spread="1.71"/>
                    <measurement group_id="O2" value="-0.682" spread="0.20"/>
                    <measurement group_id="O3" value="-1.112" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.935" spread="1.50"/>
                    <measurement group_id="O2" value="-0.658" spread="1.92"/>
                    <measurement group_id="O3" value="-1.087" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.897" spread="1.56"/>
                    <measurement group_id="O2" value="-0.764" spread="2.03"/>
                    <measurement group_id="O3" value="-1.216" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.059" spread="1.59"/>
                    <measurement group_id="O2" value="-0.896" spread="2.26"/>
                    <measurement group_id="O3" value="-1.292" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy.</title>
        <description>Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy Open Label Phase.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy.</title>
          <description>Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy Open Label Phase.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Rescue Medication Usage-Open Label Phase</title>
        <description>Rescue medication usage (number of days used) during the Open Label Phase.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Rescue Medication Usage-Open Label Phase</title>
          <description>Rescue medication usage (number of days used) during the Open Label Phase.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.172" spread="1.99"/>
                    <measurement group_id="O2" value="0.352" spread="0.68"/>
                    <measurement group_id="O3" value="1.330" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.744" spread="1.54"/>
                    <measurement group_id="O2" value="-0.793" spread="2.47"/>
                    <measurement group_id="O3" value="-1.124" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.301" spread="1.75"/>
                    <measurement group_id="O2" value="-0.671" spread="2.18"/>
                    <measurement group_id="O3" value="-1.672" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.472" spread="1.99"/>
                    <measurement group_id="O2" value="-1.180" spread="2.48"/>
                    <measurement group_id="O3" value="-1.817" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.679" spread="1.87"/>
                    <measurement group_id="O2" value="-0.418" spread="2.33"/>
                    <measurement group_id="O3" value="-0.990" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.562" spread="2.00"/>
                    <measurement group_id="O2" value="-0.745" spread="2.02"/>
                    <measurement group_id="O3" value="-0.490" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.689" spread="1.96"/>
                    <measurement group_id="O2" value="-0.959" spread="2.52"/>
                    <measurement group_id="O3" value="-0.933" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.045" spread="2.17"/>
                    <measurement group_id="O2" value="-0.553" spread="1.64"/>
                    <measurement group_id="O3" value="-0.875" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.864" spread="2.36"/>
                    <measurement group_id="O2" value="-0.577" spread="2.12"/>
                    <measurement group_id="O3" value="-1.280" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.989" spread="2.29"/>
                    <measurement group_id="O2" value="-0.359" spread="1.63"/>
                    <measurement group_id="O3" value="-1.479" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.941" spread="2.41"/>
                    <measurement group_id="O2" value="-0.980" spread="2.26"/>
                    <measurement group_id="O3" value="-1.339" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.050" spread="2.54"/>
                    <measurement group_id="O2" value="-0.767" spread="1.90"/>
                    <measurement group_id="O3" value="-1.465" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.088" spread="2.20"/>
                    <measurement group_id="O2" value="-0.929" spread="2.15"/>
                    <measurement group_id="O3" value="-2.302" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline in EuroQoL Group EQ-5D-5L Scores Over Time-Open Label Phase</title>
        <description>Change from Open Label Titration baseline in EuroQol Group 5-dimension 5-level self-report questionnaire score in the Open Label Phase. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in EuroQoL Group EQ-5D-5L Scores Over Time-Open Label Phase</title>
          <description>Change from Open Label Titration baseline in EuroQol Group 5-dimension 5-level self-report questionnaire score in the Open Label Phase. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.59" spread="13.31"/>
                    <measurement group_id="O2" value="83.38" spread="14.89"/>
                    <measurement group_id="O3" value="79.65" spread="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="15.43"/>
                    <measurement group_id="O2" value="9.95" spread="18.83"/>
                    <measurement group_id="O3" value="6.35" spread="18.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale-Open Label</title>
        <description>Summary of Change from Baseline in Clinical Global Impression of Improvement (CGI-I) scale. The Clinician Global Impression of Improvement (CGI-I) Scale is a 7-point scale that required the clinician to assess how much the subject's Pain had improved or worsened relative to the start of the study. Assessments were rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale-Open Label</title>
          <description>Summary of Change from Baseline in Clinical Global Impression of Improvement (CGI-I) scale. The Clinician Global Impression of Improvement (CGI-I) Scale is a 7-point scale that required the clinician to assess how much the subject's Pain had improved or worsened relative to the start of the study. Assessments were rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.79"/>
                    <measurement group_id="O2" value="1.7" spread="0.56"/>
                    <measurement group_id="O3" value="2.0" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.25"/>
                    <measurement group_id="O2" value="-0.1" spread="1.08"/>
                    <measurement group_id="O3" value="0.1" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline in Patient Global Impression of Improvement (PGI-I) Scale</title>
        <description>Change from baseline in the Open Label Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study. Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Patient Global Impression of Improvement (PGI-I) Scale</title>
          <description>Change from baseline in the Open Label Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study. Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.84"/>
                    <measurement group_id="O2" value="6.1" spread="1.10"/>
                    <measurement group_id="O3" value="6.3" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.16"/>
                    <measurement group_id="O2" value="-0.2" spread="1.04"/>
                    <measurement group_id="O3" value="0.5" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Open Label Phase</title>
        <description>Change from baseline in the Open Label Phase in Work Productivity and Activity Impairment score with a range of 0-100 for 4 types of scores with higher scores indicating greater impairment. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed)，Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism)，and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Open Label Phase</title>
          <description>Change from baseline in the Open Label Phase in Work Productivity and Activity Impairment score with a range of 0-100 for 4 types of scores with higher scores indicating greater impairment. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed)，Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism)，and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline-Absenteesim</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="5.55"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit-Absenteesim</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="-2.137" spread="5.23"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="18.43"/>
                    <measurement group_id="O2" value="22.9" spread="19.76"/>
                    <measurement group_id="O3" value="21.0" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit-Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="15.95"/>
                    <measurement group_id="O2" value="1.7" spread="7.53"/>
                    <measurement group_id="O3" value="6.7" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-Work Productivity Loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.846" spread="19.42"/>
                    <measurement group_id="O2" value="22.857" spread="19.76"/>
                    <measurement group_id="O3" value="21.000" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit- Work Productivity Loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="15.95"/>
                    <measurement group_id="O2" value="-0.043" spread="11.05"/>
                    <measurement group_id="O3" value="6.667" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline-Activity Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="20.55"/>
                    <measurement group_id="O2" value="29.0" spread="23.82"/>
                    <measurement group_id="O3" value="22.9" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment Visit-Activity Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="22.20"/>
                    <measurement group_id="O2" value="-6.5" spread="25.60"/>
                    <measurement group_id="O3" value="-18.2" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Discontinued Due to Loss of Efficacy</title>
        <description>Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.</description>
        <time_frame>48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
        <group_list>
          <group group_id="O1">
            <title>De Novo</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.&#xD;
buprenorphine</description>
          </group>
          <group group_id="O2">
            <title>CAM2038</title>
            <description>CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during both Double Blind Phase and Open Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Rollover Placebo Injections</title>
            <description>Placebo injections during Double Blind Phase, CAM2038 50 mg/mL q1w at doses of 4 mg, 8 mg, 12 mg orCAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg buprenorphine during Open Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discontinued Due to Loss of Efficacy</title>
          <description>Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.</description>
          <population>Modified Intent-to-Treat (mITT) Population: The mITT Population consisted of all randomized subjects, with the exception of the subjects from Sites 068 and 077 due to persistent site non-compliance</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Double Blind Phase-up to 26 weeks Open Label Phase-up to 64 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CAM2038 q1w or q4w BPN Treatment-Titration Period of Double Blind Phase</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)</description>
        </group>
        <group group_id="E2">
          <title>CAM2038 q1w or q4w BPN Treatment- Double Blind Period of Double Blind Phase</title>
          <description>CAM2038 50 mg/mL q1w at doses of 4, mg 8 mg, 12 mg, CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg. buprenorphine</description>
        </group>
        <group group_id="E3">
          <title>Placebo Subcutaneous Injections-Double Blind Period of Double Blind Phase</title>
          <description>CAM2038 placebo: 0.16, 0.18, 0.24, 0.27, 0.36, and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
        </group>
        <group group_id="E4">
          <title>De Novo Subjects-Open Label, Titration Period Only</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)</description>
        </group>
        <group group_id="E5">
          <title>Rollover Subjects-Open Label, Titration Period Only</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12, 16, 24 and 32 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection</description>
        </group>
        <group group_id="E6">
          <title>De Novo Subjects-Open Label, Enrollment Period Only</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
        </group>
        <group group_id="E7">
          <title>Rollover Subjects-Open Label, Enrollment Period Only</title>
          <description>CAM2038 q1w (buprenorphine FluidCrystal®) : SC injection depot for once weekly or monthly administration at doses of 4, 8, 12 mg (buprenorphine base) 0.16, 0.24, and 0.64 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)&#xD;
CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 mg (buprenorphine base) 0.18, 0.27, and 0.36 mL SC injection CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Triple negative breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 18.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="300" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="64" subjects_affected="64" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract injection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="468"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="468"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="468"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Franks, SVP, Head of Regulatory Affaires</name_or_title>
      <organization>Braeburn</organization>
      <phone>6104678719</phone>
      <email>sfranks@braeburnrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

